Fluorine Substitution Can Block CYP3A4 Metabolism-Dependent Inhibition:  Identification of (<i>S</i>)<i>-N</i>-[1-(4-Fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an Orally Bioavailable KCNQ2 Opener Devoid of CYP3A4 Metabolism-Dependent Inhibition

Yong‐Jin Wu(Bristol-Myers Squibb (Germany)), Michael Sinz(Rutgers, The State University of New Jersey), Craig Polson(Bristol-Myers Squibb (United States)), Digavalli V. Sivarao(Bristol-Myers Squibb (United States)), Amy Newton(Bristol-Myers Squibb (United States)), Svetlana Tertyshnikova(Bristol-Myers Squibb (United States)), William Fitzpatrick(Bristol-Myers Squibb (United States)), David T. Weaver(University of North Carolina Health Care), Mary Zoeckler(Bristol-Myers Squibb (United States)), Steven I. Dworetzky(Bristol-Myers Squibb (United States)), Huan He(Bristol-Myers Squibb (United States)), Carl D. Davis(Bristol-Myers Squibb (United States)), David Harden(Bristol-Myers Squibb (United States)), Ronald J. Knox(Bristol-Myers Squibb (United States)), Li‐Qiang Sun(Bristol-Myers Squibb (United States)), Suresh Yeola(Bristol-Myers Squibb (United States)), Thomas Philip(Bristol-Myers Squibb (Germany))
Journal of Medicinal Chemistry
July 26, 2003
Cited by 59


Related Papers